Cisplatin-induced Atrioventricular Block Requiring a Pacemaker: Two Case Reports and a Literature Review.

Pub Date : 2020-12-01 Epub Date: 2020-12-28 DOI:10.5049/EBP.2020.18.2.49
Hyun-Jin Bang, Ho Young Lee, Hyeon-Jong Kim, Namsik Yoon, Ik-Joo Chung, Woo Kyun Bae
{"title":"Cisplatin-induced Atrioventricular Block Requiring a Pacemaker: Two Case Reports and a Literature Review.","authors":"Hyun-Jin Bang,&nbsp;Ho Young Lee,&nbsp;Hyeon-Jong Kim,&nbsp;Namsik Yoon,&nbsp;Ik-Joo Chung,&nbsp;Woo Kyun Bae","doi":"10.5049/EBP.2020.18.2.49","DOIUrl":null,"url":null,"abstract":"<p><p>Chemotherapeutic drugs can cause cardiac toxicities such as cardiomyopathy, arrhythmia, and cardiovascular disease. The well-known side effects of cisplatin are nephrotoxicity, nausea, vomiting, and electrolyte imbalance. Cardiotoxicity induced by cisplatin is rare, and its pathophysiology is unknown. Here, we present two cases of complete and high-degree atrioventricular (AV) block that occurred during cisplatin-based chemotherapy and required pacemaker placement. A 64-year-old woman and a 75-year-old man, who had no underlying heart disease, developed dyspnea without chest pain and bradycardia during cisplatin-based chemotherapy. However, there were no significant differences in their serum electrolyte levels, cardiac enzyme levels, and echocardiography results before and after drug administration. The ECGs were confirmed with complete AV block and high-degree AV block, which requiring pacemaker placement. We assume that cisplatin directly caused the complete, high-degree AV block, which required a pacemaker placement in our cases. In such cases, a cumulative dose of cisplatin over 240 mg/m2 is a risk factor for early symptoms of AV block. If patients complain of dyspnea without chest pain during cisplatin-based chemotherapy, arrhythmic complications should be considered. This information may be helpful for clinicians treating patients with cisplatin chemotherapy.</p>","PeriodicalId":72889,"journal":{"name":"","volume":"18 2","pages":"49-52"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/06/ebp-18-49.PMC7781763.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5049/EBP.2020.18.2.49","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/12/28 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Chemotherapeutic drugs can cause cardiac toxicities such as cardiomyopathy, arrhythmia, and cardiovascular disease. The well-known side effects of cisplatin are nephrotoxicity, nausea, vomiting, and electrolyte imbalance. Cardiotoxicity induced by cisplatin is rare, and its pathophysiology is unknown. Here, we present two cases of complete and high-degree atrioventricular (AV) block that occurred during cisplatin-based chemotherapy and required pacemaker placement. A 64-year-old woman and a 75-year-old man, who had no underlying heart disease, developed dyspnea without chest pain and bradycardia during cisplatin-based chemotherapy. However, there were no significant differences in their serum electrolyte levels, cardiac enzyme levels, and echocardiography results before and after drug administration. The ECGs were confirmed with complete AV block and high-degree AV block, which requiring pacemaker placement. We assume that cisplatin directly caused the complete, high-degree AV block, which required a pacemaker placement in our cases. In such cases, a cumulative dose of cisplatin over 240 mg/m2 is a risk factor for early symptoms of AV block. If patients complain of dyspnea without chest pain during cisplatin-based chemotherapy, arrhythmic complications should be considered. This information may be helpful for clinicians treating patients with cisplatin chemotherapy.

Abstract Image

Abstract Image

需要起搏器的顺铂诱导房室传导阻滞:两例报告和文献综述。
化疗药物可引起心脏毒性,如心肌病、心律失常和心血管疾病。众所周知,顺铂的副作用是肾毒性、恶心、呕吐和电解质失衡。顺铂引起的心脏毒性是罕见的,其病理生理机制尚不清楚。在这里,我们报告了两个完全和高度房室(AV)传导阻滞的病例,发生在顺铂化疗期间,需要放置起搏器。一名64岁女性和一名75岁男性,无潜在心脏病,在顺铂化疗期间出现呼吸困难,无胸痛和心动过缓。然而,两组患者用药前后血清电解质水平、心酶水平及超声心动图结果均无显著差异。心电图证实为完全房室传导阻滞和高度房室传导阻滞,需要放置起搏器。我们认为顺铂直接导致完全的、高度的房室传导阻滞,在我们的病例中需要放置起搏器。在这种情况下,顺铂的累积剂量超过240mg /m2是AV阻滞早期症状的危险因素。如果患者在以顺铂为基础的化疗期间主诉呼吸困难而无胸痛,应考虑心律失常并发症。这些信息可能对临床医生治疗顺铂化疗患者有所帮助。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信